Home LiteratureArticle Details
PMID: 10516021 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

Journal of virology ·Vol. 73 ·No. 11 ·1999-11-00 ·Pages 9145-52

Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF

Abstract

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are an important parameter of host defenses that limit viral replication after infection. Induction of effective CTL against conserved viral proteins such as Gag may be essential to the development of a safe and effective HIV type 1 (HIV-1) vaccine. DNA vaccination represents a novel strategy for inducing potent CD8(+) CTL responses in vivo. However, expression of HIV-1 structural proteins by DNA vectors has been hampered by a stringent requirement for coexpression with other viral components, such as Rev and RRE. Furthermore, even with Rev and RRE present, the level of expression of HIV-1 Gag, Pol, or Env is very low in murine cells. These problems have limited our ability to address the key issue of how to generate effective CTL responses to Gag in a mouse model. To overcome this problem, we compared several novel DNA expression vectors for HIV-1 Gag protein expression in primate and mouse cells and for generating immune responses in mice after DNA vaccination. A DNA vector containing wild type HIV-1 gag coding sequences did not induce detectable Gag expression in any of the cells tested. Attempts to increase nuclear export of Gag expression RNA by adding the constitutive transport element yielded only a moderate increase in Gag expression in monkey-derived COS cells and an even lower increase in Gag expression in HeLa cells or several mouse cell lines. In contrast, silent-site mutations in the HIV-1 gag coding sequences significantly increased Gag expression levels in all cells tested. Furthermore, this construct induced both Gag-specific antibody and CTL responses in mice after DNA vaccination. Using this construct, we achieved stable expression of HIV-1 Gag in the mouse cell line p815, which can now be used as a target cell for measuring HIV-1 Gag-specific CTL responses in immunized mice. The DNA vectors described in this study should make it possible to systematically evaluate the approaches for maximizing the induction of CTL responses against HIV-1 Gag in mouse and other animal systems.

MeSH Terms
AIDS Vaccines/immunology Animals Cell Line Evaluation Studies as Topic Gene Products, gag/biosynthesis,genetics,immunology Genes, gag Genetic Vectors HIV Antibodies/blood HIV Infections/prevention & control,virology HIV-1/genetics,immunology Humans Immunoblotting Mice Mice, Inbred BALB C Protein Precursors/biosynthesis,genetics,immunology T-Lymphocytes, Cytotoxic/immunology Vaccination Vaccines, DNA/immunology
Chemicals
AIDS Vaccines Gene Products, gag HIV Antibodies Protein Precursors Vaccines, DNA p55 gag precursor protein, Human immunodeficiency virus 1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Qiu J T
Department of Molecular Microbiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205, USA.
Song R
Dettenhofer M
Tian C
August T
Felber B K
Pavlakis G N
Yu X F
References (35)
35 references, click to expand
  1. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection.
    AIDS. 1998 Apr 16;12(6):571-9 PMID: 9583596
  2. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.
    J Virol. 1998 May;72(5):3547-53 PMID: 9557634
  3. A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner.
    J Virol. 1998 Nov;72(11):9061-8 PMID: 9765451
  4. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  5. Complete nucleotide sequence of the AIDS virus, HTLV-III.
    Nature. 1985 Jan 24-30;313(6000):277-84 PMID: 2578615
  6. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa.
    Lancet. 1985 Dec 21-28;2(8469-70):1387-9 PMID: 2867393
  7. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
    J Exp Med. 1988 Oct 1;168(4):1211-24 PMID: 2459295
  8. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA.
    Proc Natl Acad Sci U S A. 1989 Mar;86(5):1495-9 PMID: 2784208
  9. A human cell factor is essential for HIV-1 Rev action.
    EMBO J. 1990 Dec;9(12):4155-60 PMID: 2249669
  10. Mechanism of action of regulatory proteins encoded by complex retroviruses.
    Microbiol Rev. 1992 Sep;56(3):375-94 PMID: 1406488
  11. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.
    J Virol. 1992 Dec;66(12):7176-82 PMID: 1433510
  12. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.
    Lancet. 1993 Apr 3;341(8849):860-1 PMID: 8096564
  13. Gene inoculation generates immune responses against human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60 PMID: 8483929
  14. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.
    Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1256-60 PMID: 8108397
  15. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients.
    J Clin Invest. 1994 Mar;93(3):1293-7 PMID: 8132769
  16. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  17. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.
    Clin Exp Immunol. 1994 Jul;97(1):61-7 PMID: 8033422
  18. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.
    Nature. 1994 Aug 11;370(6489):463-7 PMID: 8047166
  19. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  20. Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes.
    J Virol. 1994 Dec;68(12):7944-52 PMID: 7966585
  21. Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses.
    AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S43-5 PMID: 7865332
  22. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.
    Virology. 1995 May 10;209(1):147-54 PMID: 7747464
  23. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products.
    AIDS Res Hum Retroviruses. 1995 Aug;11(8):933-43 PMID: 7492440
  24. Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation.
    J Gen Virol. 1995 Dec;76 ( Pt 12):3171-9 PMID: 8847526
  25. Rev/RRE-independent Mason-Pfizer monkey virus constitutive transport element-dependent propagation of SIVmac239 vectors using a single round of replication assay.
    Virology. 1996 Aug 15;222(2):457-63 PMID: 8806531
  26. Identification of an RNA sequence within an intracisternal-A particle element able to replace Rev-mediated posttranscriptional regulation of human immunodeficiency virus type 1.
    J Virol. 1997 Jan;71(1):95-101 PMID: 8985327
  27. Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes.
    J Virol. 1997 Feb;71(2):1443-52 PMID: 8995670
  28. Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA.
    J Biol Chem. 1997 Jan 24;272(4):2307-11 PMID: 8999938
  29. DNA vaccines.
    Annu Rev Immunol. 1997;15:617-48 PMID: 9143702
  30. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.
    J Virol. 1997 Jul;71(7):4892-903 PMID: 9188551
  31. Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) functions in a position-dependent manner.
    Virology. 1997 Sep 15;236(1):118-29 PMID: 9299624
  32. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    N Engl J Med. 1997 Oct 30;337(18):1267-74 PMID: 9345075
  33. DNA immunization of mice against SIVmac239 Gag and Env using Rev-independent expression plasmids.
    AIDS Res Hum Retroviruses. 1998 Jan 1;14(1):83-90 PMID: 9453255
  34. Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells.
    Virology. 1998 Mar 30;243(1):78-93 PMID: 9527917
  35. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus.
    Mol Cell. 1998 Apr;1(5):649-59 PMID: 9660949
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1999-11-00
Pages
9145-52
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC112947
Subset
IM
Grants
NIEHS NIH HHS · T32 ES007141 · United States
NIAID NIH HHS · AI-42624 · United States
NIAID NIH HHS · AI-46324 · United States
NIEHS NIH HHS · ES07141 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]